organization · Reporting owner
FARALLON CAPITAL MANAGEMENT, L.L.C.
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Marblegate Acquisition Corp.GATE · Entity 114303 | Member of a Group Owning 10% | December 07, 2022 | December 16, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Marblegate Acquisition Corp.
Report date December 07, 2022 · Filed December 16, 2022
Jointly reported with Grassland Investors, LLC, Dreyfuss Philip D, Fisch Michael B., FRIED RICHARD B, Gehani Varun N, Giauque Nicolas, Kim David T, Linn Michael G, PATEL RAJIV A
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A common stockSEC Table I · non-derivative | Direct | 150,000 |
Reported balance
Holding disclosure · report date 2022-12-07 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 150,000 F1: The entities and individuals identified in the footnotes of this Form 3 may be deemed members of a group holding equity securities of Marblegate Acquisition Corp. (the "Issuer"). The filing of this Form 3 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such a group. F2: Since the number of reporting persons that may be listed on a Form 3 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 3 are filing one or more additional Forms 3 on the date hereof as reporting persons with respect to the securities described herein (each, a "Parallel Form 3"). Information regarding these entities and individuals is included in this Form 3 for purposes of clarification and convenience only, and is duplicative of the information reported in any Parallel Form 3. F3: The amount of securities shown in this row is owned directly by Grassland Investors, LLC ("Grassland"). |
| Class A common stockSEC Table I · non-derivative | IndirectSee Footnotes | 150,000 |
Reported balance
Holding disclosure · report date 2022-12-07 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 150,000 F1: The entities and individuals identified in the footnotes of this Form 3 may be deemed members of a group holding equity securities of Marblegate Acquisition Corp. (the "Issuer"). The filing of this Form 3 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such a group. F2: Since the number of reporting persons that may be listed on a Form 3 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 3 are filing one or more additional Forms 3 on the date hereof as reporting persons with respect to the securities described herein (each, a "Parallel Form 3"). Information regarding these entities and individuals is included in this Form 3 for purposes of clarification and convenience only, and is duplicative of the information reported in any Parallel Form 3. F3: The amount of securities shown in this row is owned directly by Grassland Investors, LLC ("Grassland"). F5: Farallon Capital Management, L.L.C. (the "Management Company"), as the manager of Grassland and Wingback, may be deemed to be a beneficial owner of the Issuer's securities held by each of Grassland and Wingback. The Management Company disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "'34 Act"), or otherwise, except to the extent of its pecuniary interest, if any. F6: Each of Philip D. Dreyfuss, Michael B. Fisch, Richard B. Fried, Varun N. Gehani, Nicolas Giauque, David T. Kim, Michael G. Linn, Rajiv A. Patel, Thomas G. Roberts, Jr., William Seybold, Andrew J. M. Spokes, John R. Warren, and Mark C. Wehrly (collectively, the "Managing Members"), as a managing member or senior managing member, as the case may be, of the Management Company, in each case with the power to exercise investment discretion, may be deemed to be a beneficial owner of the Issuer's securities held by Grassland and Wingback. Each of the Managing Members disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except to the extent of his pecuniary interest, if any. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $11.50 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-12-07 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F7: Each whole warrant of the Issuer is exercisable, pursuant to the terms thereof, for one share of Class A common stock of the Issuer on the later of 30 days after the completion of the Issuer's initial business combination and 12 months from the closing of the Issuer's initial public offering (the "IPO"). The warrants expire five years after the completion of the Issuer's initial business combination or earlier upon redemption by or liquidation of the Issuer, as described in the prospectus for the IPO. F1: The entities and individuals identified in the footnotes of this Form 3 may be deemed members of a group holding equity securities of Marblegate Acquisition Corp. (the "Issuer"). The filing of this Form 3 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such a group. F2: Since the number of reporting persons that may be listed on a Form 3 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 3 are filing one or more additional Forms 3 on the date hereof as reporting persons with respect to the securities described herein (each, a "Parallel Form 3"). Information regarding these entities and individuals is included in this Form 3 for purposes of clarification and convenience only, and is duplicative of the information reported in any Parallel Form 3. F3: The amount of securities shown in this row is owned directly by Grassland Investors, LLC ("Grassland"). |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $11.50 | IndirectSee Footnotes | Not disclosed |
Reported balance
Holding disclosure · report date 2022-12-07 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F7: Each whole warrant of the Issuer is exercisable, pursuant to the terms thereof, for one share of Class A common stock of the Issuer on the later of 30 days after the completion of the Issuer's initial business combination and 12 months from the closing of the Issuer's initial public offering (the "IPO"). The warrants expire five years after the completion of the Issuer's initial business combination or earlier upon redemption by or liquidation of the Issuer, as described in the prospectus for the IPO. F1: The entities and individuals identified in the footnotes of this Form 3 may be deemed members of a group holding equity securities of Marblegate Acquisition Corp. (the "Issuer"). The filing of this Form 3 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such a group. F2: Since the number of reporting persons that may be listed on a Form 3 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 3 are filing one or more additional Forms 3 on the date hereof as reporting persons with respect to the securities described herein (each, a "Parallel Form 3"). Information regarding these entities and individuals is included in this Form 3 for purposes of clarification and convenience only, and is duplicative of the information reported in any Parallel Form 3. F3: The amount of securities shown in this row is owned directly by Grassland Investors, LLC ("Grassland"). F5: Farallon Capital Management, L.L.C. (the "Management Company"), as the manager of Grassland and Wingback, may be deemed to be a beneficial owner of the Issuer's securities held by each of Grassland and Wingback. The Management Company disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "'34 Act"), or otherwise, except to the extent of its pecuniary interest, if any. F6: Each of Philip D. Dreyfuss, Michael B. Fisch, Richard B. Fried, Varun N. Gehani, Nicolas Giauque, David T. Kim, Michael G. Linn, Rajiv A. Patel, Thomas G. Roberts, Jr., William Seybold, Andrew J. M. Spokes, John R. Warren, and Mark C. Wehrly (collectively, the "Managing Members"), as a managing member or senior managing member, as the case may be, of the Management Company, in each case with the power to exercise investment discretion, may be deemed to be a beneficial owner of the Issuer's securities held by Grassland and Wingback. Each of the Managing Members disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except to the extent of his pecuniary interest, if any. |
| Class B common stockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-12-07 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F8: As described in and pursuant to the terms and conditions of the Issuer's certificate of incorporation, the shares of Class B common stock of the Issuer are convertible into shares of Class A common stock of the Issuer on a one-for-one basis at the time of the Issuer's initial business combination. F1: The entities and individuals identified in the footnotes of this Form 3 may be deemed members of a group holding equity securities of Marblegate Acquisition Corp. (the "Issuer"). The filing of this Form 3 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such a group. F2: Since the number of reporting persons that may be listed on a Form 3 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 3 are filing one or more additional Forms 3 on the date hereof as reporting persons with respect to the securities described herein (each, a "Parallel Form 3"). Information regarding these entities and individuals is included in this Form 3 for purposes of clarification and convenience only, and is duplicative of the information reported in any Parallel Form 3. F4: The amount of securities shown in this row is owned directly by Wingback Investors LLC ("Wingback"). |
| Class B common stockSEC Table II · derivative / convertible security | IndirectSee Footnotes | Not disclosed |
Reported balance
Holding disclosure · report date 2022-12-07 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance Not disclosed F8: As described in and pursuant to the terms and conditions of the Issuer's certificate of incorporation, the shares of Class B common stock of the Issuer are convertible into shares of Class A common stock of the Issuer on a one-for-one basis at the time of the Issuer's initial business combination. F1: The entities and individuals identified in the footnotes of this Form 3 may be deemed members of a group holding equity securities of Marblegate Acquisition Corp. (the "Issuer"). The filing of this Form 3 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such a group. F2: Since the number of reporting persons that may be listed on a Form 3 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 3 are filing one or more additional Forms 3 on the date hereof as reporting persons with respect to the securities described herein (each, a "Parallel Form 3"). Information regarding these entities and individuals is included in this Form 3 for purposes of clarification and convenience only, and is duplicative of the information reported in any Parallel Form 3. F4: The amount of securities shown in this row is owned directly by Wingback Investors LLC ("Wingback"). F5: Farallon Capital Management, L.L.C. (the "Management Company"), as the manager of Grassland and Wingback, may be deemed to be a beneficial owner of the Issuer's securities held by each of Grassland and Wingback. The Management Company disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "'34 Act"), or otherwise, except to the extent of its pecuniary interest, if any. F6: Each of Philip D. Dreyfuss, Michael B. Fisch, Richard B. Fried, Varun N. Gehani, Nicolas Giauque, David T. Kim, Michael G. Linn, Rajiv A. Patel, Thomas G. Roberts, Jr., William Seybold, Andrew J. M. Spokes, John R. Warren, and Mark C. Wehrly (collectively, the "Managing Members"), as a managing member or senior managing member, as the case may be, of the Management Company, in each case with the power to exercise investment discretion, may be deemed to be a beneficial owner of the Issuer's securities held by Grassland and Wingback. Each of the Managing Members disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except to the extent of his pecuniary interest, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The entities and individuals identified in the footnotes of this Form 3 may be deemed members of a group holding equity securities of Marblegate Acquisition Corp. (the "Issuer"). The filing of this Form 3 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such a group.
F2: Since the number of reporting persons that may be listed on a Form 3 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 3 are filing one or more additional Forms 3 on the date hereof as reporting persons with respect to the securities described herein (each, a "Parallel Form 3"). Information regarding these entities and individuals is included in this Form 3 for purposes of clarification and convenience only, and is duplicative of the information reported in any Parallel Form 3.
F3: The amount of securities shown in this row is owned directly by Grassland Investors, LLC ("Grassland").
F4: The amount of securities shown in this row is owned directly by Wingback Investors LLC ("Wingback").
F5: Farallon Capital Management, L.L.C. (the "Management Company"), as the manager of Grassland and Wingback, may be deemed to be a beneficial owner of the Issuer's securities held by each of Grassland and Wingback. The Management Company disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "'34 Act"), or otherwise, except to the extent of its pecuniary interest, if any.
F6: Each of Philip D. Dreyfuss, Michael B. Fisch, Richard B. Fried, Varun N. Gehani, Nicolas Giauque, David T. Kim, Michael G. Linn, Rajiv A. Patel, Thomas G. Roberts, Jr., William Seybold, Andrew J. M. Spokes, John R. Warren, and Mark C. Wehrly (collectively, the "Managing Members"), as a managing member or senior managing member, as the case may be, of the Management Company, in each case with the power to exercise investment discretion, may be deemed to be a beneficial owner of the Issuer's securities held by Grassland and Wingback. Each of the Managing Members disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except to the extent of his pecuniary interest, if any.
F7: Each whole warrant of the Issuer is exercisable, pursuant to the terms thereof, for one share of Class A common stock of the Issuer on the later of 30 days after the completion of the Issuer's initial business combination and 12 months from the closing of the Issuer's initial public offering (the "IPO"). The warrants expire five years after the completion of the Issuer's initial business combination or earlier upon redemption by or liquidation of the Issuer, as described in the prospectus for the IPO.
F8: As described in and pursuant to the terms and conditions of the Issuer's certificate of incorporation, the shares of Class B common stock of the Issuer are convertible into shares of Class A common stock of the Issuer on a one-for-one basis at the time of the Issuer's initial business combination.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Generation Bio Co.
Report date June 16, 2020 · Filed June 17, 2020
Jointly reported with Zone Healthcare Holdings, LLC, FARALLON PARTNERS L L C/CA, Dreyfuss Philip D, Fisch Michael B., FRIED RICHARD B, Kim David T, Linn Michael G, PATEL RAJIV A, Roberts Thomas G. Jr.
Section 16 reporting ended · disclosed 2020-06-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,918,819 |
Last balance in matching sequence
After 2020-06-16 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2020-06-16 · Conversion · Acquired 1,518,819 · Balance 1,518,819 F1: On June 16, 2020, Generation Bio Co. (the "Issuer") announced the completion of its initial public offering (the "IPO"). Upon the IPO, the outstanding Series C Preferred Stock of the Issuer converted automatically into shares of Common Stock of the Issuer on a 1.7663-for-one basis without payment of further consideration. The Series C Preferred Stock had no expiration date. F2: The entities and individuals identified in the footnotes to this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such a group. F3: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing one or more additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (each, a "Parallel Form 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in any Parallel Form 4. F4: The amount of securities shown in this row is owned directly by Zone Healthcare Holdings, LLC ("ZHH LLC"). F10: Due to the dilutive effect of the IPO, as of the completion of the IPO no reporting person on or otherwise referred to in this Form 4 or any Parallel Form 4 has beneficial ownership of more than 10% of the outstanding class of Common Stock. Row 3 · 2020-06-16 · Purchase · Acquired 400,000 · Balance 1,918,819 F2: The entities and individuals identified in the footnotes to this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such a group. F3: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing one or more additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (each, a "Parallel Form 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in any Parallel Form 4. F4: The amount of securities shown in this row is owned directly by Zone Healthcare Holdings, LLC ("ZHH LLC"). F10: Due to the dilutive effect of the IPO, as of the completion of the IPO no reporting person on or otherwise referred to in this Form 4 or any Parallel Form 4 has beneficial ownership of more than 10% of the outstanding class of Common Stock. |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-06-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-06-16 · Conversion · Disposed 2,682,691 · Balance 0 F1: On June 16, 2020, Generation Bio Co. (the "Issuer") announced the completion of its initial public offering (the "IPO"). Upon the IPO, the outstanding Series C Preferred Stock of the Issuer converted automatically into shares of Common Stock of the Issuer on a 1.7663-for-one basis without payment of further consideration. The Series C Preferred Stock had no expiration date. F2: The entities and individuals identified in the footnotes to this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such a group. F3: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing one or more additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (each, a "Parallel Form 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in any Parallel Form 4. F4: The amount of securities shown in this row is owned directly by Zone Healthcare Holdings, LLC ("ZHH LLC"). F10: Due to the dilutive effect of the IPO, as of the completion of the IPO no reporting person on or otherwise referred to in this Form 4 or any Parallel Form 4 has beneficial ownership of more than 10% of the outstanding class of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 1,518,819 |
Reported balance
Holding disclosure · report date 2020-06-16 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,518,819 F2: The entities and individuals identified in the footnotes to this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such a group. F3: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing one or more additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (each, a "Parallel Form 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in any Parallel Form 4. F4: The amount of securities shown in this row is owned directly by Zone Healthcare Holdings, LLC ("ZHH LLC"). F5: Farallon Capital Management, L.L.C. (the "Management Company"), as the manager of ZHH LLC, may be deemed to be a beneficial owner of the Issuer's securities held by ZHH LLC. The Management Company disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "'34 Act"), or otherwise, except to the extent of its pecuniary interest, if any. F6: The members of ZHH LLC are FCP SS 2019, LLC ("FCP SS"), FCIP SS 2019, LLC ("FCIP SS"), FCOI II SS 2019, Ltd. ("FCOI II SS"), Farallon Capital Institutional Partners, II, L.P. ("FCIP II"), Farallon Capital Institutional Partners III, L.P. ("FCIP III"), Four Crossings Institutional Partners V, L.P. ("FCIP V"), Farallon Special Situation Partners VI, L.P. ("FSSP VI") and Farallon Special Situations Master Fund, L.P. ("FSSF"). Each such member of ZHH LLC disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise. F7: The sole member of FCP SS is Farallon Capital Partners, L.P. ("FCP"). The sole member of FCIP SS is Farallon Capital Institutional Partners, L.P. ("FCIP"). The sole member of FCOI II SS is Farallon Capital Offshore Investors II, L.P. ("FCOI II"). Each of FCP, FCIP and FCOI II disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise. F8: Farallon Partners, L.L.C. (the "Farallon General Partner"), as the general partner of each of FCP, FCIP, FCIP II, FCIP III and FCOI II, the sole member of the respective general partners of FCIP V and FSSP VI and the sole member of the director of FCOI II SS, may be deemed to be a beneficial owner of the Issuer's securities held indirectly by each of FCP, FCIP, FCIP II, FCIP III, FCOI II, FCIP V and FSSP VI. The Farallon General Partner disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act, or otherwise, except to the extent of its pecuniary interest, if any. F9: Each of Philip D. Dreyfuss, Michael B. Fisch, Richard B. Fried, David T. Kim, Michael G. Linn, Rajiv A. Patel, Thomas G. Roberts, Jr., William Seybold, Andrew J. M. Spokes, John R. Warren, and Mark C. Wehrly (collectively, the "Managing Members"), as a managing member or senior managing member, as the case may be, of the Management Company and the Farallon General Partner, and a manager or senior manager, as the case may be, of the respective general partners of FCIP V, FSSP VI and FSSF, in each case with the power to exercise investment discretion, may be deemed to be a beneficial owner of the Issuer's securities held by ZHH LLC. Each of the Managing Members disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except to the extent of his pecuniary interest, if any. F10: Due to the dilutive effect of the IPO, as of the completion of the IPO no reporting person on or otherwise referred to in this Form 4 or any Parallel Form 4 has beneficial ownership of more than 10% of the outstanding class of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 1,918,819 |
Reported balance
Holding disclosure · report date 2020-06-16 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,918,819 F2: The entities and individuals identified in the footnotes to this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such a group. F3: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing one or more additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (each, a "Parallel Form 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in any Parallel Form 4. F4: The amount of securities shown in this row is owned directly by Zone Healthcare Holdings, LLC ("ZHH LLC"). F5: Farallon Capital Management, L.L.C. (the "Management Company"), as the manager of ZHH LLC, may be deemed to be a beneficial owner of the Issuer's securities held by ZHH LLC. The Management Company disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "'34 Act"), or otherwise, except to the extent of its pecuniary interest, if any. F6: The members of ZHH LLC are FCP SS 2019, LLC ("FCP SS"), FCIP SS 2019, LLC ("FCIP SS"), FCOI II SS 2019, Ltd. ("FCOI II SS"), Farallon Capital Institutional Partners, II, L.P. ("FCIP II"), Farallon Capital Institutional Partners III, L.P. ("FCIP III"), Four Crossings Institutional Partners V, L.P. ("FCIP V"), Farallon Special Situation Partners VI, L.P. ("FSSP VI") and Farallon Special Situations Master Fund, L.P. ("FSSF"). Each such member of ZHH LLC disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise. F7: The sole member of FCP SS is Farallon Capital Partners, L.P. ("FCP"). The sole member of FCIP SS is Farallon Capital Institutional Partners, L.P. ("FCIP"). The sole member of FCOI II SS is Farallon Capital Offshore Investors II, L.P. ("FCOI II"). Each of FCP, FCIP and FCOI II disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise. F8: Farallon Partners, L.L.C. (the "Farallon General Partner"), as the general partner of each of FCP, FCIP, FCIP II, FCIP III and FCOI II, the sole member of the respective general partners of FCIP V and FSSP VI and the sole member of the director of FCOI II SS, may be deemed to be a beneficial owner of the Issuer's securities held indirectly by each of FCP, FCIP, FCIP II, FCIP III, FCOI II, FCIP V and FSSP VI. The Farallon General Partner disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act, or otherwise, except to the extent of its pecuniary interest, if any. F9: Each of Philip D. Dreyfuss, Michael B. Fisch, Richard B. Fried, David T. Kim, Michael G. Linn, Rajiv A. Patel, Thomas G. Roberts, Jr., William Seybold, Andrew J. M. Spokes, John R. Warren, and Mark C. Wehrly (collectively, the "Managing Members"), as a managing member or senior managing member, as the case may be, of the Management Company and the Farallon General Partner, and a manager or senior manager, as the case may be, of the respective general partners of FCIP V, FSSP VI and FSSF, in each case with the power to exercise investment discretion, may be deemed to be a beneficial owner of the Issuer's securities held by ZHH LLC. Each of the Managing Members disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except to the extent of his pecuniary interest, if any. F10: Due to the dilutive effect of the IPO, as of the completion of the IPO no reporting person on or otherwise referred to in this Form 4 or any Parallel Form 4 has beneficial ownership of more than 10% of the outstanding class of Common Stock. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnotes | 0 |
Reported balance
Holding disclosure · report date 2020-06-16 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 0 F1: On June 16, 2020, Generation Bio Co. (the "Issuer") announced the completion of its initial public offering (the "IPO"). Upon the IPO, the outstanding Series C Preferred Stock of the Issuer converted automatically into shares of Common Stock of the Issuer on a 1.7663-for-one basis without payment of further consideration. The Series C Preferred Stock had no expiration date. F2: The entities and individuals identified in the footnotes to this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such a group. F3: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing one or more additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (each, a "Parallel Form 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in any Parallel Form 4. F4: The amount of securities shown in this row is owned directly by Zone Healthcare Holdings, LLC ("ZHH LLC"). F5: Farallon Capital Management, L.L.C. (the "Management Company"), as the manager of ZHH LLC, may be deemed to be a beneficial owner of the Issuer's securities held by ZHH LLC. The Management Company disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "'34 Act"), or otherwise, except to the extent of its pecuniary interest, if any. F6: The members of ZHH LLC are FCP SS 2019, LLC ("FCP SS"), FCIP SS 2019, LLC ("FCIP SS"), FCOI II SS 2019, Ltd. ("FCOI II SS"), Farallon Capital Institutional Partners, II, L.P. ("FCIP II"), Farallon Capital Institutional Partners III, L.P. ("FCIP III"), Four Crossings Institutional Partners V, L.P. ("FCIP V"), Farallon Special Situation Partners VI, L.P. ("FSSP VI") and Farallon Special Situations Master Fund, L.P. ("FSSF"). Each such member of ZHH LLC disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise. F7: The sole member of FCP SS is Farallon Capital Partners, L.P. ("FCP"). The sole member of FCIP SS is Farallon Capital Institutional Partners, L.P. ("FCIP"). The sole member of FCOI II SS is Farallon Capital Offshore Investors II, L.P. ("FCOI II"). Each of FCP, FCIP and FCOI II disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise. F8: Farallon Partners, L.L.C. (the "Farallon General Partner"), as the general partner of each of FCP, FCIP, FCIP II, FCIP III and FCOI II, the sole member of the respective general partners of FCIP V and FSSP VI and the sole member of the director of FCOI II SS, may be deemed to be a beneficial owner of the Issuer's securities held indirectly by each of FCP, FCIP, FCIP II, FCIP III, FCOI II, FCIP V and FSSP VI. The Farallon General Partner disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act, or otherwise, except to the extent of its pecuniary interest, if any. F9: Each of Philip D. Dreyfuss, Michael B. Fisch, Richard B. Fried, David T. Kim, Michael G. Linn, Rajiv A. Patel, Thomas G. Roberts, Jr., William Seybold, Andrew J. M. Spokes, John R. Warren, and Mark C. Wehrly (collectively, the "Managing Members"), as a managing member or senior managing member, as the case may be, of the Management Company and the Farallon General Partner, and a manager or senior manager, as the case may be, of the respective general partners of FCIP V, FSSP VI and FSSF, in each case with the power to exercise investment discretion, may be deemed to be a beneficial owner of the Issuer's securities held by ZHH LLC. Each of the Managing Members disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except to the extent of his pecuniary interest, if any. F10: Due to the dilutive effect of the IPO, as of the completion of the IPO no reporting person on or otherwise referred to in this Form 4 or any Parallel Form 4 has beneficial ownership of more than 10% of the outstanding class of Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 16, 2020, Generation Bio Co. (the "Issuer") announced the completion of its initial public offering (the "IPO"). Upon the IPO, the outstanding Series C Preferred Stock of the Issuer converted automatically into shares of Common Stock of the Issuer on a 1.7663-for-one basis without payment of further consideration. The Series C Preferred Stock had no expiration date.
F2: The entities and individuals identified in the footnotes to this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such a group.
F3: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing one or more additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (each, a "Parallel Form 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in any Parallel Form 4.
F4: The amount of securities shown in this row is owned directly by Zone Healthcare Holdings, LLC ("ZHH LLC").
F5: Farallon Capital Management, L.L.C. (the "Management Company"), as the manager of ZHH LLC, may be deemed to be a beneficial owner of the Issuer's securities held by ZHH LLC. The Management Company disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "'34 Act"), or otherwise, except to the extent of its pecuniary interest, if any.
F6: The members of ZHH LLC are FCP SS 2019, LLC ("FCP SS"), FCIP SS 2019, LLC ("FCIP SS"), FCOI II SS 2019, Ltd. ("FCOI II SS"), Farallon Capital Institutional Partners, II, L.P. ("FCIP II"), Farallon Capital Institutional Partners III, L.P. ("FCIP III"), Four Crossings Institutional Partners V, L.P. ("FCIP V"), Farallon Special Situation Partners VI, L.P. ("FSSP VI") and Farallon Special Situations Master Fund, L.P. ("FSSF"). Each such member of ZHH LLC disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise.
F7: The sole member of FCP SS is Farallon Capital Partners, L.P. ("FCP"). The sole member of FCIP SS is Farallon Capital Institutional Partners, L.P. ("FCIP"). The sole member of FCOI II SS is Farallon Capital Offshore Investors II, L.P. ("FCOI II"). Each of FCP, FCIP and FCOI II disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise.
F8: Farallon Partners, L.L.C. (the "Farallon General Partner"), as the general partner of each of FCP, FCIP, FCIP II, FCIP III and FCOI II, the sole member of the respective general partners of FCIP V and FSSP VI and the sole member of the director of FCOI II SS, may be deemed to be a beneficial owner of the Issuer's securities held indirectly by each of FCP, FCIP, FCIP II, FCIP III, FCOI II, FCIP V and FSSP VI. The Farallon General Partner disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act, or otherwise, except to the extent of its pecuniary interest, if any.
F9: Each of Philip D. Dreyfuss, Michael B. Fisch, Richard B. Fried, David T. Kim, Michael G. Linn, Rajiv A. Patel, Thomas G. Roberts, Jr., William Seybold, Andrew J. M. Spokes, John R. Warren, and Mark C. Wehrly (collectively, the "Managing Members"), as a managing member or senior managing member, as the case may be, of the Management Company and the Farallon General Partner, and a manager or senior manager, as the case may be, of the respective general partners of FCIP V, FSSP VI and FSSF, in each case with the power to exercise investment discretion, may be deemed to be a beneficial owner of the Issuer's securities held by ZHH LLC. Each of the Managing Members disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except to the extent of his pecuniary interest, if any.
F10: Due to the dilutive effect of the IPO, as of the completion of the IPO no reporting person on or otherwise referred to in this Form 4 or any Parallel Form 4 has beneficial ownership of more than 10% of the outstanding class of Common Stock.
Nexvet Biopharma plc
Report date July 31, 2017 · Filed August 02, 2017
Jointly reported with FARALLON PARTNERS L L C/CA, Akubra Investors, LLC, Bushranger Funding, LLC, Ute Holdings, LLC, Farallon AA G.P., L.L.C., Farallon Partners GP VI, L.L.C., NGP, L.L.C., Dreyfuss Philip D, Fisch Michael B.
Section 16 reporting ended · disclosed 2017-08-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-07-31 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2017-07-31 · Other · Disposed 833,845 · Balance 0 F14: Disposed of pursuant to a transaction agreement among the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired all of the issued and to-be-issued ordinary share capital of the Issuer (the "Acquisition"). F1: The entities and individuals identified in the footnotes of this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such group. F2: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (the "Parallel Forms 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in the Parallel Forms 4. F3: The amount of securities shown in this row is owned directly by Akubra Investors, LLC ("Akubra"). |
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-07-31 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2017-07-31 · Other · Disposed 899,268 · Balance 0 F14: Disposed of pursuant to a transaction agreement among the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired all of the issued and to-be-issued ordinary share capital of the Issuer (the "Acquisition"). F1: The entities and individuals identified in the footnotes of this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such group. F2: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (the "Parallel Forms 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in the Parallel Forms 4. F4: The amount of securities shown in this row is owned directly by Bushranger Funding, LLC ("Bushranger"). |
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-07-31 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2017-07-31 · Other · Disposed 915,583 · Balance 0 F14: Disposed of pursuant to a transaction agreement among the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired all of the issued and to-be-issued ordinary share capital of the Issuer (the "Acquisition"). F1: The entities and individuals identified in the footnotes of this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such group. F2: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (the "Parallel Forms 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in the Parallel Forms 4. F5: The amount of securities shown in this row is owned directly by Ute Holdings, LLC ("Ute" and, together with Akubra and Bushranger, the "Farallon SPVs"). |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnotes | 0 |
Reported balance
After 2017-07-31 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2017-07-31 · Other · Disposed 122,006 · Balance 0 F14: Disposed of pursuant to a transaction agreement among the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired all of the issued and to-be-issued ordinary share capital of the Issuer (the "Acquisition"). F1: The entities and individuals identified in the footnotes of this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such group. F2: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (the "Parallel Forms 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in the Parallel Forms 4. F3: The amount of securities shown in this row is owned directly by Akubra Investors, LLC ("Akubra"). F7: The members of Akubra are FCIP XR 2014, L.L.C. ("FCIP XR") and Noonday Special Situation Partners, L.P. ("NSSP") (each, a "Farallon Akubra Fund"). As the general partner of NSSP, NGP, L.L.C. (the "NSSP General Partner") may be deemed to be a beneficial owner of the Issuer's securities indirectly held by NSSP as a Farallon Akubra Fund. The NSSP General Partner disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "'34 Act"), or otherwise, except as to securities representing its pro rata interest in, and interest in the profits of, Akubra. F8: As the manager of the NSSP General Partner, Farallon Capital Management, L.L.C. (the "Management Company") may be deemed to be a beneficial owner of the Issuer's securities held by NSSP as a Farallon Akubra Fund. The Management Company disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except as to securities representing its pro rata interest in, and interest in the profits of, Akubra. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnotes | 0 |
Reported balance
After 2017-07-31 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2017-07-31 · Other · Disposed 249,462 · Balance 0 F14: Disposed of pursuant to a transaction agreement among the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired all of the issued and to-be-issued ordinary share capital of the Issuer (the "Acquisition"). F1: The entities and individuals identified in the footnotes of this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such group. F2: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (the "Parallel Forms 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in the Parallel Forms 4. F4: The amount of securities shown in this row is owned directly by Bushranger Funding, LLC ("Bushranger"). F9: The members of Bushranger are FCP XR 2014, L.L.C. ("FCP XR"), Farallon Capital Institutional Partners III, L.P. ("FCIP III"), and Farallon Capital AA Investors, L.P. ("FCAAI") (collectively, the "Farallon Bushranger Funds"). As the general partner of FCAAI, Farallon AA GP, L.L.C. (the "FCAAI GP") may be deemed to be a beneficial owner of the Issuer's securities indirectly held by FCAAI as a Farallon Bushranger Fund. The FCAAI GP disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except as to securities representing its pro rata interest in, and interest in the profits of, Bushranger. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnotes | 0 |
Reported balance
After 2017-07-31 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2017-07-31 · Other · Disposed 209,577 · Balance 0 F14: Disposed of pursuant to a transaction agreement among the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired all of the issued and to-be-issued ordinary share capital of the Issuer (the "Acquisition"). F1: The entities and individuals identified in the footnotes of this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such group. F2: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (the "Parallel Forms 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in the Parallel Forms 4. F5: The amount of securities shown in this row is owned directly by Ute Holdings, LLC ("Ute" and, together with Akubra and Bushranger, the "Farallon SPVs"). F10: The members of Ute are FCOI II SS 2014, Ltd. ("FCOI II SS"), Farallon Capital Institutional Partners II, L.P. ("FCIP II"), and Farallon Special Situation Partners VI, L.P. ("FSSP VI") (collectively, the "Farallon Ute Funds"). As the general partner of FSSP VI, Farallon Partners GP VI, L.L.C. (the "FSSP VI GP") may be deemed to be a beneficial owner of the Issuer's securities indirectly held by FSSP VI as a Farallon Ute Fund. The FSSP VI GP disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except as to securities representing its pro rata interest in, and interest in the profits of, Ute. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnotes | 0 |
Reported balance
After 2017-07-31 transaction · row 7
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 7 · 2017-07-31 · Other · Disposed 2,067,651 · Balance 0 F14: Disposed of pursuant to a transaction agreement among the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired all of the issued and to-be-issued ordinary share capital of the Issuer (the "Acquisition"). F1: The entities and individuals identified in the footnotes of this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such group. F2: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (the "Parallel Forms 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in the Parallel Forms 4. F11: As the general partner of each of (a) the sole member of FCIP XR, (b) the sole member of FCP XR, (c) FCIP III, (d) the sole member of FCOI II SS and (e) FCIP II, Farallon Partners, L.L.C. (the "Farallon General Partner") may be deemed to be a beneficial owner of the Issuer's securities indirectly held by FCIP XR as a Farallon Akubra Fund, FCP XR and FCIP III as Farallon Bushranger Funds, and FCOI II SS and FCIP II as Farallon Ute Funds. The Farallon General Partner disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except as to securities representing its pro rata interest in, and interest in the profits of, the Farallon SPVs. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnotes | 0 |
Reported balance
After 2017-07-31 transaction · row 8
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 8 · 2017-07-31 · Other · Disposed 2,648,696 · Balance 0 F14: Disposed of pursuant to a transaction agreement among the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired all of the issued and to-be-issued ordinary share capital of the Issuer (the "Acquisition"). F1: The entities and individuals identified in the footnotes of this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such group. F2: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (the "Parallel Forms 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in the Parallel Forms 4. F6: The amount of securities shown in this row is owned directly by the Farallon SPVs. F12: Each of Philip D. Dreyfuss, Michael B. Fisch, Richard B. Fried, David T. Kim, Monica R. Landry, Michael G. Linn, Ravi K. Paidipaty, Rajiv A. Patel, Thomas G. Roberts, Jr., William Seybold, John R. Warren and Mark C. Wehrly (collectively, the "Managing Members") and Andrew J. M. Spokes (the "Senior Managing Member"), as Managing Members or the Senior Managing Member, as the case may be, of both the Farallon General Partner and the Management Company, and as a manager or senior manager, as the case may be, of both the FCAAI GP and the FSSP VI GP, in each case with the power to exercise investment discretion, may be deemed to be a beneficial owner of the Issuer's securities held by the Farallon SPVs. Each of the Managing Members and the Senior Managing Member disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except to the extent of his or her pecuniary interest, if any. F13: As a director of the Issuer, Patel is filing a separate Form 4 on the date hereof. |
Filing footnotes · ownership attribution and instrument terms
F1: The entities and individuals identified in the footnotes of this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such group.
F2: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (the "Parallel Forms 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in the Parallel Forms 4.
F3: The amount of securities shown in this row is owned directly by Akubra Investors, LLC ("Akubra").
F4: The amount of securities shown in this row is owned directly by Bushranger Funding, LLC ("Bushranger").
F5: The amount of securities shown in this row is owned directly by Ute Holdings, LLC ("Ute" and, together with Akubra and Bushranger, the "Farallon SPVs").
F6: The amount of securities shown in this row is owned directly by the Farallon SPVs.
F7: The members of Akubra are FCIP XR 2014, L.L.C. ("FCIP XR") and Noonday Special Situation Partners, L.P. ("NSSP") (each, a "Farallon Akubra Fund"). As the general partner of NSSP, NGP, L.L.C. (the "NSSP General Partner") may be deemed to be a beneficial owner of the Issuer's securities indirectly held by NSSP as a Farallon Akubra Fund. The NSSP General Partner disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "'34 Act"), or otherwise, except as to securities representing its pro rata interest in, and interest in the profits of, Akubra.
F8: As the manager of the NSSP General Partner, Farallon Capital Management, L.L.C. (the "Management Company") may be deemed to be a beneficial owner of the Issuer's securities held by NSSP as a Farallon Akubra Fund. The Management Company disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except as to securities representing its pro rata interest in, and interest in the profits of, Akubra.
F9: The members of Bushranger are FCP XR 2014, L.L.C. ("FCP XR"), Farallon Capital Institutional Partners III, L.P. ("FCIP III"), and Farallon Capital AA Investors, L.P. ("FCAAI") (collectively, the "Farallon Bushranger Funds"). As the general partner of FCAAI, Farallon AA GP, L.L.C. (the "FCAAI GP") may be deemed to be a beneficial owner of the Issuer's securities indirectly held by FCAAI as a Farallon Bushranger Fund. The FCAAI GP disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except as to securities representing its pro rata interest in, and interest in the profits of, Bushranger.
F10: The members of Ute are FCOI II SS 2014, Ltd. ("FCOI II SS"), Farallon Capital Institutional Partners II, L.P. ("FCIP II"), and Farallon Special Situation Partners VI, L.P. ("FSSP VI") (collectively, the "Farallon Ute Funds"). As the general partner of FSSP VI, Farallon Partners GP VI, L.L.C. (the "FSSP VI GP") may be deemed to be a beneficial owner of the Issuer's securities indirectly held by FSSP VI as a Farallon Ute Fund. The FSSP VI GP disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except as to securities representing its pro rata interest in, and interest in the profits of, Ute.
F11: As the general partner of each of (a) the sole member of FCIP XR, (b) the sole member of FCP XR, (c) FCIP III, (d) the sole member of FCOI II SS and (e) FCIP II, Farallon Partners, L.L.C. (the "Farallon General Partner") may be deemed to be a beneficial owner of the Issuer's securities indirectly held by FCIP XR as a Farallon Akubra Fund, FCP XR and FCIP III as Farallon Bushranger Funds, and FCOI II SS and FCIP II as Farallon Ute Funds. The Farallon General Partner disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except as to securities representing its pro rata interest in, and interest in the profits of, the Farallon SPVs.
F12: Each of Philip D. Dreyfuss, Michael B. Fisch, Richard B. Fried, David T. Kim, Monica R. Landry, Michael G. Linn, Ravi K. Paidipaty, Rajiv A. Patel, Thomas G. Roberts, Jr., William Seybold, John R. Warren and Mark C. Wehrly (collectively, the "Managing Members") and Andrew J. M. Spokes (the "Senior Managing Member"), as Managing Members or the Senior Managing Member, as the case may be, of both the Farallon General Partner and the Management Company, and as a manager or senior manager, as the case may be, of both the FCAAI GP and the FSSP VI GP, in each case with the power to exercise investment discretion, may be deemed to be a beneficial owner of the Issuer's securities held by the Farallon SPVs. Each of the Managing Members and the Senior Managing Member disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except to the extent of his or her pecuniary interest, if any.
F13: As a director of the Issuer, Patel is filing a separate Form 4 on the date hereof.
F14: Disposed of pursuant to a transaction agreement among the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired all of the issued and to-be-issued ordinary share capital of the Issuer (the "Acquisition").
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2020 Filed Jun 17, 2020 21:00 UTC | Generation Bio Co. GBIO · Entity 67174 | ConversionSeries C Preferred Stock · Derivative | 2,682,691 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001214659-20-005727 · marketforms-49046.xml · derivative · entry 5 Zone Healthcare Holdings, LLC · CIK 0001814952 · 10% owner · Member of Group Owning 10% FARALLON CAPITAL MANAGEMENT LLC · CIK 0000909661 · 10% owner · Manager of ZHH LLC FARALLON PARTNERS L L C/CA · CIK 0001040153 · 10% owner · Farallon General Partner Dreyfuss Philip D · CIK 0001693981 · 10% owner · Managing Member Fisch Michael B. · CIK 0001611816 · 10% owner · Managing Member FRIED RICHARD B · CIK 0001245637 · 10% owner · Managing Member Kim David T · CIK 0001595643 · 10% owner · Managing Member Linn Michael G · CIK 0001495856 · 10% owner · Managing Member PATEL RAJIV A · CIK 0001275110 · 10% owner · Managing Member Roberts Thomas G. Jr. · CIK 0001453042 · 10% owner · Managing Member Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,518,819 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On June 16, 2020, Generation Bio Co. (the "Issuer") announced the completion of its initial public offering (the "IPO"). Upon the IPO, the outstanding Series C Preferred Stock of the Issuer converted automatically into shares of Common Stock of the Issuer on a 1.7663-for-one basis without payment of further consideration. The Series C Preferred Stock had no expiration date. F1 · price: On June 16, 2020, Generation Bio Co. (the "Issuer") announced the completion of its initial public offering (the "IPO"). Upon the IPO, the outstanding Series C Preferred Stock of the Issuer converted automatically into shares of Common Stock of the Issuer on a 1.7663-for-one basis without payment of further consideration. The Series C Preferred Stock had no expiration date. F1 · derivative.exercise_date: On June 16, 2020, Generation Bio Co. (the "Issuer") announced the completion of its initial public offering (the "IPO"). Upon the IPO, the outstanding Series C Preferred Stock of the Issuer converted automatically into shares of Common Stock of the Issuer on a 1.7663-for-one basis without payment of further consideration. The Series C Preferred Stock had no expiration date. F1 · derivative.expiration_date: On June 16, 2020, Generation Bio Co. (the "Issuer") announced the completion of its initial public offering (the "IPO"). Upon the IPO, the outstanding Series C Preferred Stock of the Issuer converted automatically into shares of Common Stock of the Issuer on a 1.7663-for-one basis without payment of further consideration. The Series C Preferred Stock had no expiration date. F2 · ownership.direct: The entities and individuals identified in the footnotes to this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such a group. F3 · ownership.direct: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing one or more additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (each, a "Parallel Form 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in any Parallel Form 4. F4 · ownership.direct: The amount of securities shown in this row is owned directly by Zone Healthcare Holdings, LLC ("ZHH LLC"). F10 · ownership.direct: Due to the dilutive effect of the IPO, as of the completion of the IPO no reporting person on or otherwise referred to in this Form 4 or any Parallel Form 4 has beneficial ownership of more than 10% of the outstanding class of Common Stock. Read SEC document |
| June 16, 2020 Filed Jun 17, 2020 21:00 UTC | Generation Bio Co. GBIO · Entity 67174 | PurchaseCommon Stock | 400,000 | $19.00 | $7,600,000.00 |
DisclosureSEC source: 0001214659-20-005727 · marketforms-49046.xml · nonDerivative · entry 3 Zone Healthcare Holdings, LLC · CIK 0001814952 · 10% owner · Member of Group Owning 10% FARALLON CAPITAL MANAGEMENT LLC · CIK 0000909661 · 10% owner · Manager of ZHH LLC FARALLON PARTNERS L L C/CA · CIK 0001040153 · 10% owner · Farallon General Partner Dreyfuss Philip D · CIK 0001693981 · 10% owner · Managing Member Fisch Michael B. · CIK 0001611816 · 10% owner · Managing Member FRIED RICHARD B · CIK 0001245637 · 10% owner · Managing Member Kim David T · CIK 0001595643 · 10% owner · Managing Member Linn Michael G · CIK 0001495856 · 10% owner · Managing Member PATEL RAJIV A · CIK 0001275110 · 10% owner · Managing Member Roberts Thomas G. Jr. · CIK 0001453042 · 10% owner · Managing Member Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,918,819 F2 · ownership.direct: The entities and individuals identified in the footnotes to this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such a group. F3 · ownership.direct: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing one or more additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (each, a "Parallel Form 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in any Parallel Form 4. F4 · ownership.direct: The amount of securities shown in this row is owned directly by Zone Healthcare Holdings, LLC ("ZHH LLC"). F10 · ownership.direct: Due to the dilutive effect of the IPO, as of the completion of the IPO no reporting person on or otherwise referred to in this Form 4 or any Parallel Form 4 has beneficial ownership of more than 10% of the outstanding class of Common Stock. Read SEC document |
| June 16, 2020 Filed Jun 17, 2020 21:00 UTC | Generation Bio Co. GBIO · Entity 67174 | ConversionCommon Stock | 1,518,819 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001214659-20-005727 · marketforms-49046.xml · nonDerivative · entry 1 Zone Healthcare Holdings, LLC · CIK 0001814952 · 10% owner · Member of Group Owning 10% FARALLON CAPITAL MANAGEMENT LLC · CIK 0000909661 · 10% owner · Manager of ZHH LLC FARALLON PARTNERS L L C/CA · CIK 0001040153 · 10% owner · Farallon General Partner Dreyfuss Philip D · CIK 0001693981 · 10% owner · Managing Member Fisch Michael B. · CIK 0001611816 · 10% owner · Managing Member FRIED RICHARD B · CIK 0001245637 · 10% owner · Managing Member Kim David T · CIK 0001595643 · 10% owner · Managing Member Linn Michael G · CIK 0001495856 · 10% owner · Managing Member PATEL RAJIV A · CIK 0001275110 · 10% owner · Managing Member Roberts Thomas G. Jr. · CIK 0001453042 · 10% owner · Managing Member Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,518,819 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On June 16, 2020, Generation Bio Co. (the "Issuer") announced the completion of its initial public offering (the "IPO"). Upon the IPO, the outstanding Series C Preferred Stock of the Issuer converted automatically into shares of Common Stock of the Issuer on a 1.7663-for-one basis without payment of further consideration. The Series C Preferred Stock had no expiration date. F2 · ownership.direct: The entities and individuals identified in the footnotes to this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such a group. F3 · ownership.direct: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing one or more additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (each, a "Parallel Form 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in any Parallel Form 4. F4 · ownership.direct: The amount of securities shown in this row is owned directly by Zone Healthcare Holdings, LLC ("ZHH LLC"). F10 · ownership.direct: Due to the dilutive effect of the IPO, as of the completion of the IPO no reporting person on or otherwise referred to in this Form 4 or any Parallel Form 4 has beneficial ownership of more than 10% of the outstanding class of Common Stock. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 19:54 UTC | Nexvet Biopharma plc NVET · Entity 174046 | OtherOrdinary Shares | 2,648,696 | $6.72 | $17,799,237.12 |
DisclosureSEC source: 0001182489-17-000447 · edgar.xml · nonDerivative · entry 8 FARALLON CAPITAL MANAGEMENT LLC · CIK 0000909661 · 10% owner · Member of Group Owning 10% FARALLON PARTNERS L L C/CA · CIK 0001040153 · 10% owner · Member of Group Owning 10% Akubra Investors, LLC · CIK 0001632596 · 10% owner · Member of Group Owning 10% Bushranger Funding, LLC · CIK 0001632625 · 10% owner · Member of Group Owning 10% Ute Holdings, LLC · CIK 0001632627 · 10% owner · Member of Group Owning 10% Farallon AA G.P., L.L.C. · CIK 0001632734 · 10% owner · Member of Group Owning 10% Farallon Partners GP VI, L.L.C. · CIK 0001632735 · 10% owner · Member of Group Owning 10% NGP, L.L.C. · CIK 0001632660 · 10% owner · Member of Group Owning 10% Dreyfuss Philip D · CIK 0001693981 · 10% owner · Member of Group Owning 10% Fisch Michael B. · CIK 0001611816 · 10% owner · Member of Group Owning 10% Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 F14 · price: Disposed of pursuant to a transaction agreement among the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired all of the issued and to-be-issued ordinary share capital of the Issuer (the "Acquisition"). F1 · ownership.nature: The entities and individuals identified in the footnotes of this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such group. F2 · ownership.nature: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (the "Parallel Forms 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in the Parallel Forms 4. F6 · ownership.nature: The amount of securities shown in this row is owned directly by the Farallon SPVs. F12 · ownership.nature: Each of Philip D. Dreyfuss, Michael B. Fisch, Richard B. Fried, David T. Kim, Monica R. Landry, Michael G. Linn, Ravi K. Paidipaty, Rajiv A. Patel, Thomas G. Roberts, Jr., William Seybold, John R. Warren and Mark C. Wehrly (collectively, the "Managing Members") and Andrew J. M. Spokes (the "Senior Managing Member"), as Managing Members or the Senior Managing Member, as the case may be, of both the Farallon General Partner and the Management Company, and as a manager or senior manager, as the case may be, of both the FCAAI GP and the FSSP VI GP, in each case with the power to exercise investment discretion, may be deemed to be a beneficial owner of the Issuer's securities held by the Farallon SPVs. Each of the Managing Members and the Senior Managing Member disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except to the extent of his or her pecuniary interest, if any. F13 · ownership.nature: As a director of the Issuer, Patel is filing a separate Form 4 on the date hereof. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 19:54 UTC | Nexvet Biopharma plc NVET · Entity 174046 | OtherOrdinary Shares | 2,067,651 | $6.72 | $13,894,614.72 |
DisclosureSEC source: 0001182489-17-000447 · edgar.xml · nonDerivative · entry 7 FARALLON CAPITAL MANAGEMENT LLC · CIK 0000909661 · 10% owner · Member of Group Owning 10% FARALLON PARTNERS L L C/CA · CIK 0001040153 · 10% owner · Member of Group Owning 10% Akubra Investors, LLC · CIK 0001632596 · 10% owner · Member of Group Owning 10% Bushranger Funding, LLC · CIK 0001632625 · 10% owner · Member of Group Owning 10% Ute Holdings, LLC · CIK 0001632627 · 10% owner · Member of Group Owning 10% Farallon AA G.P., L.L.C. · CIK 0001632734 · 10% owner · Member of Group Owning 10% Farallon Partners GP VI, L.L.C. · CIK 0001632735 · 10% owner · Member of Group Owning 10% NGP, L.L.C. · CIK 0001632660 · 10% owner · Member of Group Owning 10% Dreyfuss Philip D · CIK 0001693981 · 10% owner · Member of Group Owning 10% Fisch Michael B. · CIK 0001611816 · 10% owner · Member of Group Owning 10% Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 F14 · price: Disposed of pursuant to a transaction agreement among the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired all of the issued and to-be-issued ordinary share capital of the Issuer (the "Acquisition"). F1 · ownership.nature: The entities and individuals identified in the footnotes of this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such group. F2 · ownership.nature: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (the "Parallel Forms 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in the Parallel Forms 4. F11 · ownership.nature: As the general partner of each of (a) the sole member of FCIP XR, (b) the sole member of FCP XR, (c) FCIP III, (d) the sole member of FCOI II SS and (e) FCIP II, Farallon Partners, L.L.C. (the "Farallon General Partner") may be deemed to be a beneficial owner of the Issuer's securities indirectly held by FCIP XR as a Farallon Akubra Fund, FCP XR and FCIP III as Farallon Bushranger Funds, and FCOI II SS and FCIP II as Farallon Ute Funds. The Farallon General Partner disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except as to securities representing its pro rata interest in, and interest in the profits of, the Farallon SPVs. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 19:54 UTC | Nexvet Biopharma plc NVET · Entity 174046 | OtherOrdinary Shares | 209,577 | $6.72 | $1,408,357.44 |
DisclosureSEC source: 0001182489-17-000447 · edgar.xml · nonDerivative · entry 6 FARALLON CAPITAL MANAGEMENT LLC · CIK 0000909661 · 10% owner · Member of Group Owning 10% FARALLON PARTNERS L L C/CA · CIK 0001040153 · 10% owner · Member of Group Owning 10% Akubra Investors, LLC · CIK 0001632596 · 10% owner · Member of Group Owning 10% Bushranger Funding, LLC · CIK 0001632625 · 10% owner · Member of Group Owning 10% Ute Holdings, LLC · CIK 0001632627 · 10% owner · Member of Group Owning 10% Farallon AA G.P., L.L.C. · CIK 0001632734 · 10% owner · Member of Group Owning 10% Farallon Partners GP VI, L.L.C. · CIK 0001632735 · 10% owner · Member of Group Owning 10% NGP, L.L.C. · CIK 0001632660 · 10% owner · Member of Group Owning 10% Dreyfuss Philip D · CIK 0001693981 · 10% owner · Member of Group Owning 10% Fisch Michael B. · CIK 0001611816 · 10% owner · Member of Group Owning 10% Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 F14 · price: Disposed of pursuant to a transaction agreement among the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired all of the issued and to-be-issued ordinary share capital of the Issuer (the "Acquisition"). F1 · ownership.nature: The entities and individuals identified in the footnotes of this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such group. F2 · ownership.nature: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (the "Parallel Forms 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in the Parallel Forms 4. F5 · ownership.nature: The amount of securities shown in this row is owned directly by Ute Holdings, LLC ("Ute" and, together with Akubra and Bushranger, the "Farallon SPVs"). F10 · ownership.nature: The members of Ute are FCOI II SS 2014, Ltd. ("FCOI II SS"), Farallon Capital Institutional Partners II, L.P. ("FCIP II"), and Farallon Special Situation Partners VI, L.P. ("FSSP VI") (collectively, the "Farallon Ute Funds"). As the general partner of FSSP VI, Farallon Partners GP VI, L.L.C. (the "FSSP VI GP") may be deemed to be a beneficial owner of the Issuer's securities indirectly held by FSSP VI as a Farallon Ute Fund. The FSSP VI GP disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except as to securities representing its pro rata interest in, and interest in the profits of, Ute. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 19:54 UTC | Nexvet Biopharma plc NVET · Entity 174046 | OtherOrdinary Shares | 249,462 | $6.72 | $1,676,384.64 |
DisclosureSEC source: 0001182489-17-000447 · edgar.xml · nonDerivative · entry 5 FARALLON CAPITAL MANAGEMENT LLC · CIK 0000909661 · 10% owner · Member of Group Owning 10% FARALLON PARTNERS L L C/CA · CIK 0001040153 · 10% owner · Member of Group Owning 10% Akubra Investors, LLC · CIK 0001632596 · 10% owner · Member of Group Owning 10% Bushranger Funding, LLC · CIK 0001632625 · 10% owner · Member of Group Owning 10% Ute Holdings, LLC · CIK 0001632627 · 10% owner · Member of Group Owning 10% Farallon AA G.P., L.L.C. · CIK 0001632734 · 10% owner · Member of Group Owning 10% Farallon Partners GP VI, L.L.C. · CIK 0001632735 · 10% owner · Member of Group Owning 10% NGP, L.L.C. · CIK 0001632660 · 10% owner · Member of Group Owning 10% Dreyfuss Philip D · CIK 0001693981 · 10% owner · Member of Group Owning 10% Fisch Michael B. · CIK 0001611816 · 10% owner · Member of Group Owning 10% Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 F14 · price: Disposed of pursuant to a transaction agreement among the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired all of the issued and to-be-issued ordinary share capital of the Issuer (the "Acquisition"). F1 · ownership.nature: The entities and individuals identified in the footnotes of this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such group. F2 · ownership.nature: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (the "Parallel Forms 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in the Parallel Forms 4. F4 · ownership.nature: The amount of securities shown in this row is owned directly by Bushranger Funding, LLC ("Bushranger"). F9 · ownership.nature: The members of Bushranger are FCP XR 2014, L.L.C. ("FCP XR"), Farallon Capital Institutional Partners III, L.P. ("FCIP III"), and Farallon Capital AA Investors, L.P. ("FCAAI") (collectively, the "Farallon Bushranger Funds"). As the general partner of FCAAI, Farallon AA GP, L.L.C. (the "FCAAI GP") may be deemed to be a beneficial owner of the Issuer's securities indirectly held by FCAAI as a Farallon Bushranger Fund. The FCAAI GP disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except as to securities representing its pro rata interest in, and interest in the profits of, Bushranger. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 19:54 UTC | Nexvet Biopharma plc NVET · Entity 174046 | OtherOrdinary Shares | 122,006 | $6.72 | $819,880.32 |
DisclosureSEC source: 0001182489-17-000447 · edgar.xml · nonDerivative · entry 4 FARALLON CAPITAL MANAGEMENT LLC · CIK 0000909661 · 10% owner · Member of Group Owning 10% FARALLON PARTNERS L L C/CA · CIK 0001040153 · 10% owner · Member of Group Owning 10% Akubra Investors, LLC · CIK 0001632596 · 10% owner · Member of Group Owning 10% Bushranger Funding, LLC · CIK 0001632625 · 10% owner · Member of Group Owning 10% Ute Holdings, LLC · CIK 0001632627 · 10% owner · Member of Group Owning 10% Farallon AA G.P., L.L.C. · CIK 0001632734 · 10% owner · Member of Group Owning 10% Farallon Partners GP VI, L.L.C. · CIK 0001632735 · 10% owner · Member of Group Owning 10% NGP, L.L.C. · CIK 0001632660 · 10% owner · Member of Group Owning 10% Dreyfuss Philip D · CIK 0001693981 · 10% owner · Member of Group Owning 10% Fisch Michael B. · CIK 0001611816 · 10% owner · Member of Group Owning 10% Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 F14 · price: Disposed of pursuant to a transaction agreement among the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired all of the issued and to-be-issued ordinary share capital of the Issuer (the "Acquisition"). F1 · ownership.nature: The entities and individuals identified in the footnotes of this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such group. F2 · ownership.nature: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (the "Parallel Forms 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in the Parallel Forms 4. F3 · ownership.nature: The amount of securities shown in this row is owned directly by Akubra Investors, LLC ("Akubra"). F7 · ownership.nature: The members of Akubra are FCIP XR 2014, L.L.C. ("FCIP XR") and Noonday Special Situation Partners, L.P. ("NSSP") (each, a "Farallon Akubra Fund"). As the general partner of NSSP, NGP, L.L.C. (the "NSSP General Partner") may be deemed to be a beneficial owner of the Issuer's securities indirectly held by NSSP as a Farallon Akubra Fund. The NSSP General Partner disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "'34 Act"), or otherwise, except as to securities representing its pro rata interest in, and interest in the profits of, Akubra. F8 · ownership.nature: As the manager of the NSSP General Partner, Farallon Capital Management, L.L.C. (the "Management Company") may be deemed to be a beneficial owner of the Issuer's securities held by NSSP as a Farallon Akubra Fund. The Management Company disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except as to securities representing its pro rata interest in, and interest in the profits of, Akubra. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 19:54 UTC | Nexvet Biopharma plc NVET · Entity 174046 | OtherOrdinary Shares | 915,583 | $6.72 | $6,152,717.76 |
DisclosureSEC source: 0001182489-17-000447 · edgar.xml · nonDerivative · entry 3 FARALLON CAPITAL MANAGEMENT LLC · CIK 0000909661 · 10% owner · Member of Group Owning 10% FARALLON PARTNERS L L C/CA · CIK 0001040153 · 10% owner · Member of Group Owning 10% Akubra Investors, LLC · CIK 0001632596 · 10% owner · Member of Group Owning 10% Bushranger Funding, LLC · CIK 0001632625 · 10% owner · Member of Group Owning 10% Ute Holdings, LLC · CIK 0001632627 · 10% owner · Member of Group Owning 10% Farallon AA G.P., L.L.C. · CIK 0001632734 · 10% owner · Member of Group Owning 10% Farallon Partners GP VI, L.L.C. · CIK 0001632735 · 10% owner · Member of Group Owning 10% NGP, L.L.C. · CIK 0001632660 · 10% owner · Member of Group Owning 10% Dreyfuss Philip D · CIK 0001693981 · 10% owner · Member of Group Owning 10% Fisch Michael B. · CIK 0001611816 · 10% owner · Member of Group Owning 10% Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F14 · price: Disposed of pursuant to a transaction agreement among the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired all of the issued and to-be-issued ordinary share capital of the Issuer (the "Acquisition"). F1 · ownership.direct: The entities and individuals identified in the footnotes of this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such group. F2 · ownership.direct: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (the "Parallel Forms 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in the Parallel Forms 4. F5 · ownership.direct: The amount of securities shown in this row is owned directly by Ute Holdings, LLC ("Ute" and, together with Akubra and Bushranger, the "Farallon SPVs"). Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 19:54 UTC | Nexvet Biopharma plc NVET · Entity 174046 | OtherOrdinary Shares | 899,268 | $6.72 | $6,043,080.96 |
DisclosureSEC source: 0001182489-17-000447 · edgar.xml · nonDerivative · entry 2 FARALLON CAPITAL MANAGEMENT LLC · CIK 0000909661 · 10% owner · Member of Group Owning 10% FARALLON PARTNERS L L C/CA · CIK 0001040153 · 10% owner · Member of Group Owning 10% Akubra Investors, LLC · CIK 0001632596 · 10% owner · Member of Group Owning 10% Bushranger Funding, LLC · CIK 0001632625 · 10% owner · Member of Group Owning 10% Ute Holdings, LLC · CIK 0001632627 · 10% owner · Member of Group Owning 10% Farallon AA G.P., L.L.C. · CIK 0001632734 · 10% owner · Member of Group Owning 10% Farallon Partners GP VI, L.L.C. · CIK 0001632735 · 10% owner · Member of Group Owning 10% NGP, L.L.C. · CIK 0001632660 · 10% owner · Member of Group Owning 10% Dreyfuss Philip D · CIK 0001693981 · 10% owner · Member of Group Owning 10% Fisch Michael B. · CIK 0001611816 · 10% owner · Member of Group Owning 10% Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F14 · price: Disposed of pursuant to a transaction agreement among the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired all of the issued and to-be-issued ordinary share capital of the Issuer (the "Acquisition"). F1 · ownership.direct: The entities and individuals identified in the footnotes of this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such group. F2 · ownership.direct: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (the "Parallel Forms 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in the Parallel Forms 4. F4 · ownership.direct: The amount of securities shown in this row is owned directly by Bushranger Funding, LLC ("Bushranger"). Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 19:54 UTC | Nexvet Biopharma plc NVET · Entity 174046 | OtherOrdinary Shares | 833,845 | $6.72 | $5,603,438.40 |
DisclosureSEC source: 0001182489-17-000447 · edgar.xml · nonDerivative · entry 1 FARALLON CAPITAL MANAGEMENT LLC · CIK 0000909661 · 10% owner · Member of Group Owning 10% FARALLON PARTNERS L L C/CA · CIK 0001040153 · 10% owner · Member of Group Owning 10% Akubra Investors, LLC · CIK 0001632596 · 10% owner · Member of Group Owning 10% Bushranger Funding, LLC · CIK 0001632625 · 10% owner · Member of Group Owning 10% Ute Holdings, LLC · CIK 0001632627 · 10% owner · Member of Group Owning 10% Farallon AA G.P., L.L.C. · CIK 0001632734 · 10% owner · Member of Group Owning 10% Farallon Partners GP VI, L.L.C. · CIK 0001632735 · 10% owner · Member of Group Owning 10% NGP, L.L.C. · CIK 0001632660 · 10% owner · Member of Group Owning 10% Dreyfuss Philip D · CIK 0001693981 · 10% owner · Member of Group Owning 10% Fisch Michael B. · CIK 0001611816 · 10% owner · Member of Group Owning 10% Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F14 · price: Disposed of pursuant to a transaction agreement among the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired all of the issued and to-be-issued ordinary share capital of the Issuer (the "Acquisition"). F1 · ownership.direct: The entities and individuals identified in the footnotes of this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such group. F2 · ownership.direct: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (the "Parallel Forms 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in the Parallel Forms 4. F3 · ownership.direct: The amount of securities shown in this row is owned directly by Akubra Investors, LLC ("Akubra"). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.